Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasal Polyps

Interventions

BIOLOGICAL: Depemokimab (GSK3511294)
DRUG: Placebo

Sponsor

GlaxoSmithKline